REZOLUTE, INC. Accumulated Other Comprehensive Income
REZOLUTE, INC. (RZLT) had Accumulated Other Comprehensive Income of -$119.00 thousand as of 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-09-24
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$119.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$115.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $47.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $49.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$119.00K 10-K · filed 2026-09-24 |
| 2026-03-31 | -$115.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $47.00K 10-Q · filed 2026-02-12 |
| 2025-09-30 | $49.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$7.00K 10-K · filed 2026-09-24 |
| 2025-03-31 | $43.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $64.00K 10-Q · filed 2025-02-12 |
| 2024-09-30 | $289.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$79.00K 10-K · filed 2025-09-17 |
| 2024-03-31 | -$78.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$48.00K 10-Q · filed 2024-02-13 |
| 2023-09-30 | -$284.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$351.00K 10-K · filed 2024-09-19 |
| 2023-03-31 | -$132.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |